Перейти к основному содержанию
AkademIndex

Продукты

Для разработчиков

AkademBaseОткрытый API экосистемы
← Назад к работе

Работы, на которые ссылается эта работа

Работ: 47

Работа: Repurposing of Rutan showed effective treatment for COVID-19 disease

  1. Coronavirus biology and replication: implications for SARS-CoV-2

    Philip V’kovski, Annika Kratzel, Silvio Steiner +2

    Обзорная статья2020Цитирований: 6
    ABI

  2. More than 50 long-term effects of COVID-19: a systematic review and meta-analysis

    Sandra López‐León, Talía Wegman-Ostrosky, Carol Perelman +4

    Обзорная статья2021Цитирований: 5
    ABI

  3. Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors

    Zhenming Jin, Xiaoyu Du, Yechun Xu +28

    Статья2020Цитирований: 5
    ABI

  4. COVID-19: Emergence, Spread, Possible Treatments, and Global Burden

    Raghuvir Keni, Anila Alexander, Pawan G. Nayak +2

    Обзорная статья2020Цитирований: 4
    ABI

  5. Evaluation of green tea polyphenols as novel corona virus (SARS CoV-2) main protease (Mpro) inhibitors – an <i>in silico</i> docking and molecular dynamics simulation study

    Rajesh Ghosh, Ayon Chakraborty, Ashis Biswas +1

    Статья2020Цитирований: 4
    ABI

  6. Inhibition of the SARS-CoV-2 3CLpro main protease by plant polyphenols

    Miha Bahun, Marko Jukič, Domen Oblak +7

    Статья2021Цитирований: 4
    ABI

  7. Safety, tolerability, and pharmacokinetics of a single ascending dose of baicalein chewable tablets in healthy subjects

    Min Li, Aixin Shi, Hongxian Pang +10

    Статья2014Цитирований: 3
    ABI

  8. C-reactive protein and the acute phase response

    Mark B. Pepys

    Статья1982Цитирований: 3
    ABI

  9. Virus-encoded proteinases and proteolytic processing in the Nidovirales

    John Ziebuhr, Alexander E. Gorbalenya, Eric J. Snijder

    Обзорная статья2000Цитирований: 3
    ABI

  10. Design of Wide-Spectrum Inhibitors Targeting Coronavirus Main Proteases

    Haitao Yang, Weiqing Xie, Xiaoyu Xue +16

    Статья2005Цитирований: 3
    ABI

  11. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials

    K. F Schulz, D. G Altman, D. Moher +1

    Статья2010Цитирований: 3
    ABI

  12. STRUCTURE OF POLYPHENOLS OF LEAVES TANNING SUMAC RHUS CORIARIA L.

    Zhamollitdin Fazlitdinovich Ziyavitdinov, Yuliya Igorevna Oshchepkova, N. G. Abdulladzhanova +1

    Статья2020Цитирований: 3
    ABI

  13. Compassionate Use of Remdesivir for Patients with Severe Covid-19

    Jonathan Grein, Norio Ohmagari, Daniel D. Shin +53

    Статья2020Цитирований: 3
    ABI

  14. Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir

    Wanchao Yin, Chunyou Mao, Xiaodong Luan +19

    Статья2020Цитирований: 3
    ABI

  15. Plasma CRP level is positively associated with the severity of COVID-19

    Wei Chen, Kenneth I. Zheng, Saiduo Liu +3

    Статья2020Цитирований: 3
    ABI

  16. A review of the safety of favipiravir – a potential treatment in the COVID-19 pandemic?

    Victoria Pilkington, Toby Pepperrell, Andrew Hill

    Обзорная статья2020Цитирований: 3
    ABI

  17. Clinical characteristics of children with COVID-19: a rapid review and meta-analysis

    on behalf of COVID-19 Evidence and Recommendations Working Group, Zijun Wang, Qi Zhou +16

    Обзорная статья2020Цитирований: 3
    ABI

  18. Systemic <i>In Silico</i> Screening in Drug Discovery for Coronavirus Disease (COVID-19) with an Online Interactive Web Server

    Chi Xu, Zunhui Ke, Chuandong Liu +15

    Статья2020Цитирований: 3
    ABI

  19. Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial

    Zarir Udwadia, Pawan Singh, Hanmant Barkate +7

    Статья2020Цитирований: 3
    ABI

  20. Repurposing drugs for the management of COVID-19

    Jacopo Cusinato, Ylenia Cau, Anna Maria Calvani +1

    Обзорная статья2020Цитирований: 3
    ABI

  21. Alkaloids and flavonoids from African phytochemicals as potential inhibitors of SARS-Cov-2 RNA-dependent RNA polymerase: an<i>in silico</i>perspective

    Oludare M. Ogunyemi, Gideon Ampoma Gyebi, Abdo A. Elfiky +4

    Статья2020Цитирований: 3
    ABI

  22. Identification of existing pharmaceuticals and herbal medicines as inhibitors of SARS-CoV-2 infection

    Jia-Tsrong Jan, Ting-Jen Rachel Cheng, Yu-Pu Juang +14

    Статья2021Цитирований: 3
    ABI

  23. <i>Scutellaria baicalensis</i> extract and baicalein inhibit replication of SARS-CoV-2 and its 3C-like protease <i>in vitro</i>

    Hongbo Liu, Fei Ye, Qi Sun +7

    Статья2021Цитирований: 3
    ABI

  24. Characterising proteolysis during SARS-CoV-2 infection identifies viral cleavage sites and cellular targets with therapeutic potential

    Bjoern Meyer, Jeanne Chiaravalli, Stacy Gellenoncourt +16

    Статья2021Цитирований: 3
    ABI

  25. Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19

    Jennifer Hammond, Heidi Leister-Tebbe, Annie Gardner +9

    Статья2022Цитирований: 3
    ABI